Purpose: To evaluate performances of published gene signatures for the assessment of urothelial carcinoma.
Urothelial cancer is the fifth most common cancer in the western world (1) . Approximately 75% of the newly diagnosed cases show a nonmuscle-invasive (NMI) growth pattern, tumor stages Ta and T1, whereas the remaining are more aggressive and invade the surrounding muscle and adjacent organs, tumor stages ≥ T2 (2) . Tumor grade is associated with tumor stage and almost all NMI cancers are of low grade (G 1 and G 2 ), whereas nearly all muscleinvasive (MI) tumors are of high grade (G3). The 5-year relative survival rate is 81%, but only ∼50% for patients with muscle-invasive tumors (3) . Roughly 20% of the nonmuscle tumor patients progress to invasive growth. Most superficial tumors (Ta and T1) are treated with transurethral resection, whereas MI tumors are subjected to cystectomy. A characteristic feature of patients with superficial tumors treated with transurethral resection is frequent local recurrences. The risk of progression as well as the frequent recurrences require extensive clinical management of bladder cancer patients, and therefore, this patient group is estimated to have a considerable lifetime cost (4) . Intravesical treatment, neoadjuvant, and adjuvant chemotherapy positively modify disease outcome.
The main current prognostic tools are based on histologic stage and grade, but multifocality, recurrence rate, tumor size, and concomitant carcinoma in situ also influence the course of disease (5) . A large number of molecular markers have been described in the literature (6) , but few have entered into clinical decision making. In recent years, several investigations have used genome-wide gene expression analyses to define specific gene expression signatures associated with both urothelial cancer biology and the clinical course of the disease (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Many of these have the potential to be of great clinical value. The signatures have been derived by various means including clustering methods (e.g., hierarchical clustering analysis) or inference (e.g., t test) and, in some cases, by more advanced classification algorithms that both derive the gene signatures and evaluate their performances (7-9, 11, 13, 17) . Validation of the suggested gene signatures in independent external data sets is, however, scarce (8, 9, 17, 21) , which may lead to an overestimation of gene signature performance and robustness.
In the present investigation, we investigate to what extent proposed gene signatures may predict urothelial cancer stage, grade, and survival in independent gene expression data sets. To evaluate robustness of prediction, we use four different published gene expression data sets for validation and two different classification algorithms. All together, we tested 28 bladder cancer-derived gene signatures and 11 signatures derived for nonurothelial cancers. We show that stage and grade are predicted well, whereas survival is predicted very poorly. We also reveal a consistent structure in bladder cancer expression data associated with tumor stage and grade that has implications for biomarker discovery, and that using large gene signatures (>150 members) is a prerequisite for robust and accurate prediction.
Materials and Methods

Gene signatures
A total of 28 bladder cancer gene signatures from 14 studies (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , as well as 11 nonbladder cancer-derived gene signatures devised for various purposes (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) were extracted from the literature (Supplementary Table S1 ). GeneSymbols in the signatures were updated using the official HGNC GeneSymbols downloaded from the HGNC Web site (33) . All gene signature records without an associated HGNC GeneSymbol were discarded. Original and updated GeneSymbols are found in Supplementary Table S1 .
Data sets
For validation, we used four different data sets produced by Sanchez Table S4 of ref. 8 ) was imputed for missing values using k-nearest neighbors (k = 10) for genes that had no >20% missing data, and genes with >20% missing data were omitted (36) . For the Dyrskjøt data set (Gene Expression Omnibus: GSE88 and GSE89), RMA expression values were obtained from the cel files using the affy package (37) of the R project Bioconductor (38) . The SanchezC data set (Supplementary Table S10 of ref. 7) was quantile normalized using the normalizeBetweenArrays function of the limma package (39) . RMA was done separately for two samples sets of the Stransky data set (ArrayExpress: E-TABM-147; on U95A and U95Av2, respectively). Obtained RMA expression values were delogged; the sample sets were merged; and was quantile normalized using limma. The SanchezC and Stransky data sets were both transformed to log 2 scale. To obtain gene-centered log 2 values, the gene expression values were subtracted by the mean expression of the gene for each of the three Affymetrix data sets (SanchezC, Stransky, and Dyrskjøt) separately. The HGNC GeneSymbols were updated in all data sets as described above. The expression values of GeneSymbols with multiple reporters were merged by taking the median expression value. All entries in the data sets without a GeneSymbol were discarded. The final SanchezC data set contained 90 patients and 12,761 genes; the Blaveri data set contained 74 patients and 4,430 genes; the Dyrskjøt data set contained 66 patients and 5,370 genes; and the Stransky data set contained 55 patients and 8,955 genes. For classification, Ta and T1 cases were considered NMI; ≥T2 cases were considered as MI; grade 1 was considered low grade; and grade 2 and 3 as high grade (40) . Exceptions were made for the Dyrskjøt data, in which their transformation of the Bergkvist grading was applied (9) , and the SanchezC data, for which the classification was made between grade 2 and grade 3 patients because this data set contained only grade 2 and 3 patients.
Classification
The GeneSymbols of a gene signature present in the respective validation data set were used for classification. We used two algorithms for classification, support vector machine (SVM) and nearest centroid classifier (NCC). We used the SVM function of the R package e1071 (41), a linear kernel to avoid over fitting, and the default setting for cost = 1. For NCC, we applied the R implementation of PAM (42) with a shrinkage threshold = 0, which reduces the PAM algorithm to a NCC. No parameters were tuned in the NCC or in the SVM algorithm to optimize the predictions. For both algorithms, a leave-one-out-crossvalidation loop was done to assign predictions for all cases. Predicted and true classes were compared by a confusion matrix using the R package caret to obtain accuracy,
Translational Relevance
During the past years, whole-genome gene expression analyses of urothelial carcinomas have shown promising results with respect to classification and stratification. In addition, several potential gene signatures designed for tumor prognosis have been described. A limitation in most of these studies is, however, that validation in independent data is rarely done. Furthermore, it has been hard to compare signature performances as unique data sets and algorithms have been used. We undertake a systematic evaluation of 28 gene signatures, assessed in four different and independent data sets, with the aim to clarify their performance. We show that stage and grade signatures perform well, that none of the tested survival signatures could be validated in external data, and that larger signatures than the published thus far are needed to obtain robust predictions. We believe that the present investigation represents a critical step in the translation of gene signatures into clinical practice. specificity, sensitivity, positive predictive value, and negative predictive value. A one-sided P value for the obtained accuracies to be better than random assignments was calculated using a binominal test. This approach for random assignments takes the prior sample distribution into account, e.g., in the case of 70% MI patients, the probability of any sample to be classified as MI is 0.7. Briefly, accuracies for random assignment are slightly better than 0.5 for unbalanced distributions and are calculated as the square of the fraction of samples in one sample class plus the square of the fraction of samples in the other class (i.e., for the example above one gets 0.7 2 + 0.3 2 = 0.58 as the expected accuracy for random assignments).
Additional statistical analyses
Gene Ontology and KEGG analyses were done using DAVID (43) , and the whole genome was used as reference. When subsets of genes in the individual validation sets were analyzed, all genes in the respective data set were used as reference. We used an false discovery rate (FDR) of 5% as cutoff for significance. Randomized data sets were produced by replacing the real data set with random samples from a normal distribution with the mean and SD of the original data set. For correlation analyses, randomization was done additionally by permuting the sample labels 1,000 times. Hazard ratios (HR) were obtained by Cox regression using the survival package in R. Finally, the R package pamr was used to determine the optimal death signature having the smallest error in the training set when using the default 10-fold cross-validation.
Results
Gene signatures
We collected 28 predictor gene signatures for urothelial cancer from the literature ( Table 1) . These were grouped into predictors for pathologic stage (n = 8), pathologic grade (n = 5), progression (n = 4), death (n = 6), and other purposes (n = 5). To evaluate the extent to which bladder derived gene signatures performed better than nonbladder gene signatures, we included 11 nonbladder cancerderived gene signatures from the literature ( Table 1 ). The most frequently enriched biological processes as determined by gene ontology (GO) term analysis were cell cycle related, with no specificity for any of the gene signature categories, whereas the most frequently enriched cellular compartment categories were related to extracellular compartment, particularly frequent in the stage predictors (Supplementary Table S3 ). The most frequently enriched KEGG pathways were "Cell Cycle", "Focal Adhesion," and "Cellular Communication." We then tested the extent of overlap among the urothelial cancer gene signatures designed for the same purposes (Supplementary Table S4) . In this comparison, we excluded variant gene signatures produced by the same research groups as these would introduce redundancy. The proportion of genes that are present in more than one signature was relatively low, 11%, 7%, 4%, and 0.6%, among the stage, grade, progression, and death predictors, respectively, and no gene was present in all signatures of a prediction category. A GO term and a KEGG pathway analysis revealed that the shared genes in the stage predictors showed enrichment for the GO terms "developmental process" and "extracellular region part," and the KEGG pathway Focal Adhesion. On the other hand, the genes shared by the grade predictors showed significant enrichment for "mitosis," "spindle," and the KEGG pathway Cell Cycle, whereas no significant GO terms were found for the shared genes in the progression or in the death signatures. From this, we conclude that although the published gene signatures show very little overlap, at least the stage and grade signatures are enriched for shared biological processes.
Evaluation of stage predictors
We first used stage-related signatures to predict NMI and MI cases using the SVM approach. Genes in predictor signatures also present in the validation data sets were fed into the SVM and then used for prediction. As a consequence, the number of included genes varied somewhat with data sets (Supplementary Table S5 ). The mean prediction accuracies ranged from 0.72 to 0.89 in the four data sets and were significantly higher than obtained by random assignments (Table 2 ). The obtained accuracies did not differ significantly from those obtained in the original publications using the original algorithms (Supplementary Table S6) . Surprisingly, both the nonstage bladder-derived signatures as well as the nonbladderderived signatures on average performed just as well. Equivalent mean accuracies were obtained using the parallel NCC analyses (Table 2 ; for mean sensitivities and specificities, see Supplementary Table S7 ). Ranking the signatures with respect to obtained accuracies (Supplementary Table S8 ; Fig. 1 ) revealed, as expected, that signatures derived from the data set used for validation always were among the top signatures. Many of the nonbladder cancerderived gene signatures performed very well, e.g., in the Dyrskjøt data set, and excluding the Dyrskjøt_T.all signature, the top-ranking signature is the grade-orientated gene signature Kim_G.all followed by two nonbladder-derived gene signatures, Chang_WoundResponse and Lauss_ Breast. We also noticed that the ranks of individual gene signatures varied with the validation data sets, e.g., the Blaveri_T.all showed the ranks 2, 2, 19, and 24 in the Blaveri, SanchezC, Dyrskjøt, and Stransky data, respectively. The results for the NCC algorithm were similar but did not show the same top signatures in the respective rank lists (Supplementary Table S8 ). Taken together, no signature has an overall better performance, and nonstage and nonbladder signatures may perform better than bladderderived stage signatures. We then investigated to what extent the cases were concordantly classified (Fig. 2A) . In the Blaveri data set, a total of 40 (54%) patients were uniformly classified by all eight-stage signatures, and 56 cases (76%) were uniformly classified by at least 7 of the signatures. Two cases were uniformly classified into the opposite class compared with the original pathologic classification. Similar results were obtained for the other data sets. We conclude that although the overlap of genes in the respective gene signatures is very low, the prediction accuracies are similar and fairly good, but that agreement in patient predictions is moderate (Mean Cohen's κ for agreement among two signatures = 0.64; range = 0.34-0.89).
We then wanted to compare the results obtained with the published and specific gene signatures with gene signatures picked at random. For these purposes, we systematically generated 100 random and independent gene signatures, ranging from 5 to 500 members in steps of five, and calculated the accuracy for each one of them. In Fig. 2B , we have plotted the accuracies obtained with the bladder-derived stage predictions, the bladder nonstage predictors, nonbladder-derived signatures, together with the obtained accuracies for the 100 randomly picked signatures. Intriguingly, large enough random gene sets performed just as well, or better, than the specifically made gene signatures. The largest 50 of the 100 randomly selected signatures predict NMI/MI using SVM within the range of 0.86 to 0.96 in the Blaveri data set (mean = 0.91). Furthermore, the concordance for patient prediction among the random signatures was higher than for the specifically derived gene signatures (Fig. 2C) . The mean Cohen's κ for prediction agreement among the large randomly picked signatures was 0.88, ranging from 0.63 to 1. The overlap among the random gene signatures is, however, small, e.g., the two largest random signatures within each category have an average overlap of 11% in the Blaveri data set and 4% in the SanchezC data set, respectively, as expected by the hypergeometric distribution. Similar results were obtained for all four data sets using both the SVM and NCC algorithms ( Supplementary Fig. S1 ). Strikingly, only 1 of 28 bladder cancer gene signatures performed better than the best random gene signature in all data sets using the SVM approach. When the generation of randomly picked gene signatures is repeated 100 times, the mean accuracy of the random signatures is increasing as the number of signature genes increases, whereas SD of accuracy drops ( Supplementary Fig. S2 ). When, on the other hand, the investigation was repeated using a randomized version of the SanchezC data set, accuracies close to random assignments were obtained ( Supplementary Fig. S3 ).
The above results indicate that the randomly picked gene signatures capture some fundamental aspect of the data related to NMI/MI. To explore this further, we calculated the correlation to NMI/MI status for each gene in each data set and compared this to randomized data. It is obvious from Fig. 2D that a large proportion of genes show a higher correlation with NMI/MI status than expected by random events. Similar results were obtained for all four data sets. The proportion of genes that exceeded the 99% limit of the randomized distribution ranged from 19% in the Dyrskjøt data set to 37% in the Blaveri data set. Furthermore, a moderate but highly significant correlation (r = 0.495; P < 1E-15) exists between the genes associated with NMI/MI status in the SanchezC data and genes associated with NMI/MI status in the Blaveri data (Fig. 2E) . To reveal biological themes within the data, we performed GO term and KEGG pathway analyses of the genes that showed correlations larger than the 99% limits of the randomized data. All data sets showed enrichment for "metabolic process," "mitochondrion," and "ribosome" among the genes associated with NMI and several GO terms and KEGG pathways, including "immune response," "response to wounding," "cell adhesion," and "extracellular matrix," among genes associated with MI (Supplementary Table S9 ). This indicates that randomly picked gene signatures from any of the four data sets ) . Importantly, this is not a valid predictor for the SanchezC data set, as correlation has been calculated using all patients before cross-validation. Thus, the patients to be classified in the cross-validation have already "seen" the data set. The goal is to apply top-ranked genes derived from one data set to validation data, a valid procedure.
will contain a substantial proportion of biologically coherent genes correlated with NMI/MI status.
However, even if genes associated with MI status in different data sets are correlated, high performances by short predictor signatures may be compromised in validation data sets due to small sample size effects. This may be seen in Fig. 2B that suggests that accuracy increases and accuracy variance decreases with signature size. To investigate the influence of gene signature size on accuracy in validation data further, we first rank ordered the genes in the SanchezC data with respect to correlation with NMI/MI status and then selected the top-correlated genes using gene lists of increasing sizes (top 5 to top 500, in steps of five). The obtained gene lists were then used for predictions in the Blaveri, Dyrskjøt, and Stransky data sets using SVM. The results clearly show that performance increases with increasing signature size, and that robust predictors are obtained when the gene signatures exceed ∼150 members (Fig. 2F) . To test if this size effect also applies to the published gene signatures, we used the ranks obtained in Fig. 1 to generate rank products for each signature. In this scenario, a gene signature that consistently performs well across the validation data sets would have a small rank product. We then plotted the logged rank products against the gene signature size (Supplementary Fig. S4 ). The obtained plot shows that the rank products are significantly negatively correlated (r = −0.54; P = 0.0004) and that large gene signatures (>200) perform better than shorter.
Evaluation of tumor grade predictors
The mean prediction accuracies for grade using the grade-specific predictors and SVM ranged from 0.75 in the Dyrskjøt data set to 0.86 in the Blaveri data set, and both nongrade and nonbladder-derived signatures performed equally well ( Table 2 ). The rank of the individual signatures in the respective validation sets varied considerably (Supplementary Table S10 ), and hence, no single gene signature outperformed the others. The concordance in grade prediction among the different grade signatures was moderate to high; in the Blaveri data set, a total of 53 (72%) patients were uniformly classified by all five signatures, and 68 cases (92%) were uniformly classified by at least four of the signatures. Three cases were uniformly classified into the opposite class compared with the original pathologic classification. As for tumor stage, a general structure in the data related to tumor grade was seen (Fig. 3A) , and accordingly, randomly selected gene signatures larger than 150 generally performed equally well, or better, as the specifically designed signatures (Fig. 3B) . Robustness of the randomly selected gene signatures was shown by the fact that the 50 largest randomly selected signatures assigned 49 of the cases (66%) in full agreement (Fig. 3C) , close to the concordance obtained with five of the specifically designed signatures. The mean Cohen's κ for agreement among the grade signatures was 0.31 (range = 0.00-0.72), whereas the mean Cohen's κ for the large randomly picked signatures was 0.63 (range = 0.31-1). As for the NMI/MI status predictors, we produced gene signatures with increasing sizes based on the topcorrelated genes in the SanchezC data set and applied these signatures to the Blaveri, Dyrskjøt, and Stransky data sets. Similar to our results for the NMI/MI status signatures, this analysis revealed that gene signatures exceeding ∼150 genes produced stable prediction accuracies in the respective validation data sets (Fig. 3D) .
Evaluation of survival predictors
For validation of the death predictor signatures, only two data sets, SanchezC and Blaveri, could be used, as they were the only data sets with survival data. The bladderspecific death predictors produced average accuracies of 0.58 (range = 0.51-0.63) and 0.51 (range = 0.41-0.59) in independent validation, hardly better than expected by random assignments ( Table 2 ). The two top death predictors in the SanchezC validation data set were derived from this same data set and produced accuracies of 0.82 and 0.74 (Supplementary Table S5 ). However, when applied to the Blaveri data set, accuracies were reduced to 0.41 and 0.59, respectively, i.e., close to random assignment. Neither the bladder-specific nondeath nor the nonbladder signatures performed better. Essentially, the same results were obtained with the NCC algorithm. As it may be argued that death predictors are more applicable to patients with MI tumors, the analyses were repeated in this subset of patients. This, however, did not improve the accuracies (Table 2) . Moreover, randomly selected gene signatures with increasing size did not perform better than random assignments (Fig. 4A) . We investigated to what extent the gene signatures still were of prognostic value by Cox regression. The only signature that showed significant HRs in the Blaveri data set, the only data set from which time to death was available, was the Blaveri_surv.MI signature produced from the same data set. Hence, not one of the other 38 gene signatures had a convincing prognostic potential when applied to an external data set (Fig. 4B) .
We then produced gene signatures based on the genes top correlated to death in the SanchezC data and applied them to the Blaveri data using SVM. It is obvious from Fig. 4C that, in contrast to the NMI/MI and grade situation, this approach does not improve the accuracy by which death is predicted. This agrees with the findings that no correlations to death larger than expected from a randomized data set is observed in the SanchezC data ( Fig. 4D and E) , and by the absence of correlations among genes associated with death in the SanchesC data and with genes associated with death the Blaveri data (Fig. 4F) . A likely explanation for these results is that the observed correlations are caused by chance events that cannot be reproduced in independent data. If the analysis is repeated using gender as the distinguishing feature, the same result is obtained, except that 8 Y-chromosome genes show correlations (0.53-0.85) to gender stronger than expected from randomized data. Hence, if there had been a few genes strongly associated with death in the data sets, they would have been identified in the previous analysis.
To exclude any incompatibility between the published gene signatures for outcome and the algorithms used in the present investigation, we established new gene signatures using the PAM algorithm. We then used the obtained gene signatures as a starting point for NCC analyses as described above, using the SanchezC data for training and the Blaveri data set for validation, and the reverse. These analyses resulted in accuracies only slightly larger than obtained by random assignment, also when limiting the analysis to MI cases only (Supplementary Table S11 ). Increasing the gene signature size to 150, compared with 8 to 33 in the previous analyses, did not improve the results. Even if a moderate increase in accuracy was observed in some cases, none of the obtained accuracies were significantly different from random assignments (FDR > 5%).
Discussion
Our assumption in the present investigation was that robust gene signatures should capture fundamental biological characteristics relevant for the feature/process in question and be independent from the algorithm and data set used for prediction. We therefore evaluated the published gene signatures using two algorithms in parallel, the simpler NCC (NCC/PAM) algorithm and the more sophisticated SVM. Both algorithms showed similar overall performances and produced accuracies comparable with what was obtained using the respective gene signatures in the original publications. Hence, we have no reason to believe that the obtained results have been influenced by the particular statistical tools used.
The investigated bladder-derived stage and grade predictors were found to be fairly robust and performed well in the validation data. Furthermore, also the nonstage/grade signatures as well as nonbladder derived signatures performed equally well. Our results also showed that no single gene signature outperformed the others. This is in line with results obtained by Ein-Dor et al. (44) , showing that a large number of alternative gene signatures with equal prediction performances may be derived from a given data set, and that the exact nature of molecular signatures is strongly dependent on the composition of the training set (45) . Unexpectedly, however, we found that randomly picked gene signatures performed just as well, or better, as the specific gene signatures, particularly when the random gene signatures included >150 genes, a considerably larger Fig. 3 . Prediction of grade. Legend for A to D as in Fig. 1D , B, C and F, respectively. C, top-correlated genes to death from SanchezC data set used as a predictor in Blaveri ( • ) and Sanchez C ( ○ , overfitted). D and E, genes correlated to survival/death in the Blaveri data set. Dotted line, randomized data using normal distribution; dashed line, randomized data using sample label permutation; solid line, real data (Blaveri data set). F, correlation to survival/death in two data sets. r, Pearson correlation coefficient. Plots are for MI patients except for D, which is for all patients.
number than was generally seen in the published gene signatures. These results indicated that randomly picked gene signatures captured an overall stage/grade-related structure in the data. This was confirmed by comparing correlations with stage/grade obtained with the original and randomized data, respectively, which showed that a significant fraction of the genes in fact was correlated with stage and grade. This was also revealed by the fact that all data sets showed consistent upregulation of immunerelated genes in high-stage tumors, whereas high-grade tumors consistently show enrichment of proliferation genes. These results also explain why the published stage/grade predictors performed almost equally well, although they only shared a small fraction of the genes; they most likely represent different small selections from a large number of genes with expression patterns discriminating stages and grades, respectively (44, 46) . This was also shown by the finding that the published gene signatures were enriched for GO terms and KEGG pathways also enriched among the genes that showed an overall correlation to stage or grade. The observed correlation structures were, however, composed of genes that showed moderate correlations to tumor stage or grade. In addition, some genes that showed convincing correlations in one data set could show weak or even opposite correlation in another data set. A consequence of this is that short predictor gene signatures, showing good performance in a training set using LOOCV, run the risk of being corrupted when applied to validation data sets due to small sample size effects. This consequence became obvious when we used the top-correlated genes in one data set and applied them, with increasing gene signature sizes, as gene predictors in validation data sets. In this setting, gene signatures with >150 members were needed to obtain robust predictors. A possible explanation for this finding is that large gene signatures are less likely to be affected by chance fluctuations caused by technical or other sources. In addition, whereas large randomly picked gene signatures produced a good agreement in patient predictions, producing Cohen's κ values of 0.88 and 0.63 for stage and grade, respectively, the shorter published gene signatures agreed less well, producing Cohen κ values of 0.64 and 0.31, respectively. A possible explanation for this is that a short gene signature is less likely to capture tumor heterogeneity than a more extensive gene signature. Hence, our results suggest that a requirement for stable and reproducible prediction results is large gene signatures (44) .
In contrast to stage and grade, none of the investigated signatures could predict death as outcome when applied to external data. The performances did not improve when we limited the analysis to MI tumors only. Furthermore, the accuracies obtained in the validation data did not improve when we used the strategy of selecting top-correlated genes and increasing the signature sizes, as was the case for the stage and grade situation; instead, the accuracies remained close to what was obtained by random assignments. Even when we applied the PAM algorithm to design completely new gene signatures, these did not perform well in validation data sets. The cause for these results became obvious when the original correlations to survival were compared with correlation with randomized data; there were few, if any, genes that showed stronger association with survival than expected by chance events. As a consequence, any survival predictor with good performance in a training set will deteriorate in a validation data set, also in agreement with the very small overlap, 0.6%, seen among the death-related gene signatures. Furthermore, no signature produced convincing HRs when applied to the Blaveri data set, except the Blaveri_surv_MI signature, which was derived from the same data set. These findings are in contrast to what has been observed for breast cancer for which survival gene signatures have been validated and significant HR have been obtained in external data sets (47) (48) (49) (50) (51) (52) .
There may be several explanations for these findings. One could be that the analyzed tumor samples are not representative for the aggressive part of the tumor, e.g., by limiting the analysis to the superficial part of the tumors obtained by transurethral resection. Alternatively, factors that may influence survival could possibly have a restricted localization, e.g., to the invasion front of the tumor, and may not be well represented in the bulk of tumor material. In addition, the ability to define robust prognostic gene signatures may be dependent on the stratification of urothelial cancer into further molecular subtypes, as has been shown to be the case for breast cancer (53) . In estrogen receptor-positive (ER+) breast cancer, a proliferation signature shows the best correlation with survival, whereas an immune response signature shows the best correlation in ER− tumors. Hence, any potential subtype-specific gene signatures may be masked by treating, e.g., MI urothelial cancer cases as one single group. This emphasizes the importance of a more thorough molecular characterization of urothelial cancer, and of invasive tumors in particular, to allow for a more detailed molecular stratification. We cannot, however, exclude that a limited number of genes in fact may have a strong effect on survival, and that these genes were not represented in the data sets. Irrespectively, our data indicates that special precautions have to be made when designing survival signatures for urothelial cancer and that validation in independent data sets is essential. In addition, more advanced algorithms that include, e.g., more complex dependencies among genes or information of the host (patient), may have to be considered.
We conclude that the most likely explanation for the similar performance of published stage/grade gene signatures, although they do not overlap in respect to composition, is that they represent different small selections of genes form a large number of discriminatory genes. We also conclude that gene signatures larger than 150 genes are required, at least with the current sample sizes available in bladder cancer data, to produce robust gene signatures with maintained performance in independent data. The finding that not one signature for survival could be validated in independent data emphasizes that special considerations have to be taken when designing new gene signatures for outcome in bladder cancer.
